Supplements used to advantage

Abstract

A recent (January 2010) editorial in The Lancet addressing the “perils of journal and supplement publishing” states in no unclear terms that the publishing of commercially sponsored supplements is “firmly off the agenda” for The Lancet. The editorial notes that although supplements and custom publications are an established element in journal publishing, supplemental material “is usually much inferior to that of any parent title” and is generally problematic for editors and reviewers. On this note, The Lancet goes on to identify examples of commercial supplement publications that support this view, including a recent example that had fallen into their own hands.

(Published: 8 April 2010)

Citation: Global Health Action 2010, 3: 5166 - DOI: 10.3402/gha.v3i0.5166